Carlsbad, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio,” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and ...
Carlsbad, CA, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio,” or the “Company”), a clinical-stage ...
Agomab Therapeutics is taking its lead candidate, ontunisertib, to a Phase IIb trial following its mid-stage success in fibrostenosing Crohn’s disease (FSCD). During the Phase IIa STENOVA study ...
ANTWERP, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab’) today announced positive interim results from 44 patients completing treatment in the ongoing STENOVA 1 Phase 2a clinical trial for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results